Skip to main content
New Year’s Sale — Build a balanced news diet with 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

Transgene Publishes Phase I Data Supporting TG4050's Potential in Preventing Head and Neck Cancer Relapse

Summary by Benzinga
TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext PARIS:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the preprint publication on medRxiv of a comprehen…

1 Articles

BenzingaBenzinga
Center

Transgene Publishes Phase I Data Supporting TG4050's Potential in Preventing Head and Neck Cancer Relapse

TG4050 elicits strong polyepitopic, polyclonal, durable cytotoxic and effector neoantigen-specific CD8 T cell responses Results reinforce TG4050 potential as an individualized cancer immunotherapy Strasbourg, France, January 9, 2026, 8:00 a.m. CET – Transgene (Euronext PARIS:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced the preprint publication on medRxiv of a comprehen…

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Friday, January 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Strasbourg icon

Strasbourg

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal